



Polymer Factory Sweden AB (publ)

Interim Report Q3 2025

Third quarter, July-September 2025

- Polymer Factory completes strategic delivery to Leading Biopharmaceutical Company based in Boston area
- Dendritic nanogels (DNGs) based on Polymer Factory's proprietary bis-MPA dendritic nanotechnology show promise as nanocarrier against aggressive tumors
- Polymer Factory Granted SpheriCal Patent and Dendritic Nanogel (DNG) Patent in Multiple European Countries
- Polymer Factory Receives Approx. SEK 2.05 Million Through 100% Exercise of Warrants of Series TO1
- Polymer Factory announced change of management

Comments from CEO Mats Wallnér

I am truly impressed by the caliber of customers choosing our products – many of them are world-leading organizations at the forefront of their industries. This is a strong validation of the quality, innovation, and customer value that Polymer Factory's technology delivers.

“Each QSee™ vial contains only 5 micrograms of SpheriCal®, yet sells for an impressive market price of SEK 13,300”

Strategic Collaborations with Bruker and Merck

Our collaboration with Bruker continues to progress well, with joint evaluations of new application areas for SpheriCal® across multiple fields. Earlier this year, Bruker launched QSee™ – a quality control suite of software and reference materials based on SpheriCal®, enabling automated instrument performance evaluation. Each QSee™ vial contains only 5 micrograms of SpheriCal®, yet sells for an impressive market price of SEK 13,300. This market position reflects both the strong commercial potential and the high perceived value of our technology.

Polymer Factory also maintains a long-standing partnership with Merck Sigma Aldrich, acting as a global distributor of around thirty of our products. The collaboration continues to perform well, and our goal is to expand it into new product areas, strengthening our global footprint and market reach.

Expanding Market Applications

Our proprietary products are applied across a diverse range of industries and research domains. Within IVF (in vitro fertilization), they contribute to improved knowledge and reduced risks; in cancer diagnostics, they enable solutions previously considered impossible; and in dermatology, they enhance skin penetration and therapeutic efficacy. Beyond these areas, our products are used in several other applications, often by customers whose specific projects remain confidential. Our customer base includes global corporations, innovative start-ups, clinics, and some of the world's top-ranked universities.

Customer Growth and Commercial Focus

It is encouraging to see growing recognition of Polymer Factory and the value our solutions bring to customers. During the quarter, we have strengthened our commercial outreach, taking

more structured and proactive measures to identify and engage with potential customers where our technology offers clear competitive advantages. The majority of our customer base is located in North America and Europe – two key markets where we continue to see solid traction.

Market Environment and Outlook

The global environment remains characterized by uncertainty stemming from complex geopolitical conditions, trade and tariff risks, high asset prices, and concerns over persistent inflation. Despite these challenges, our outlook for the remainder of 2025 and into 2026 remains positive. The world-leading companies we collaborate with recognize both the unique value our products deliver and the deep scientific expertise within Polymer Factory.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-11-2025 08:00 CET.

For more information, please contact:

Mats Wallner, Acting CEO

Phone: +46 (0) 70 951 95 06

E-mail: mats.wallner@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.